These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29637849)

  • 1. Diverse Targeted Approaches to Battle Multidrug Resistance in Cancer.
    Shankaraiah N; Nekkanti S; Ommi O; P S LS
    Curr Med Chem; 2019; 26(39):7059-7080. PubMed ID: 29637849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of multidrug resistance in the age of targeted therapy.
    Türk D; Szakács G
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer.
    Yuan Y; Cai T; Xia X; Zhang R; Chiba P; Cai Y
    Drug Deliv; 2016 Nov; 23(9):3350-3357. PubMed ID: 27098896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
    Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
    Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib-zinc phthalocyanine conjugates as potential agents for enhancing synergistic therapy of multidrug-resistant cancer by glutathione depletion.
    Wei G; Huang L; Jiang Y; Shen Y; Huang Z; Huang Y; Sun X; Zhao C
    Eur J Med Chem; 2019 May; 169():53-64. PubMed ID: 30856406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.
    Nobili S; Landini I; Mazzei T; Mini E
    Med Res Rev; 2012 Nov; 32(6):1220-62. PubMed ID: 21374643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
    Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G
    Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological strategies for overcoming multidrug resistance.
    Nobili S; Landini I; Giglioni B; Mini E
    Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research Progress in Reversal of Tumor Multi-drug Resistance via Natural Products.
    Guo Q; Cao H; Qi X; Li H; Ye P; Wang Z; Wang D; Sun M
    Anticancer Agents Med Chem; 2017 Nov; 17(11):1466-1476. PubMed ID: 29034843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer.
    Dinic J; Podolski-Renic A; Stankovic T; Bankovic J; Pesic M
    Curr Pharm Des; 2015; 21(38):5589-604. PubMed ID: 26429711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers.
    Zhou G; Latchoumanin O; Hebbard L; Duan W; Liddle C; George J; Qiao L
    Adv Drug Deliv Rev; 2018 Sep; 134():107-121. PubMed ID: 29627370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
    Wijdeven RH; Pang B; Assaraf YG; Neefjes J
    Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial Surface Engineering for Multidrug Resistance Reversal.
    Chen W; Shi K; Chu B; Wei X; Qian Z
    Nano Lett; 2019 May; 19(5):2905-2913. PubMed ID: 30935203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells.
    Shekari F; Sadeghpour H; Javidnia K; Saso L; Nazari F; Firuzi O; Miri R
    Eur J Pharmacol; 2015 Jan; 746():233-44. PubMed ID: 25445037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRP1-dependent Collateral Sensitivity of Multidrug-resistant Cancer Cells: Identifying Selective Modulators Inducing Cellular Glutathione Depletion.
    Lorendeau D; Dury L; Nasr R; Boumendjel A; Teodori E; Gutschow M; Falson P; Di Pietro A; Baubichon-Cortay H
    Curr Med Chem; 2017; 24(12):1186-1213. PubMed ID: 27855620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence.
    Sawicka M; Kalinowska M; Skierski J; Lewandowski W
    J Pharm Pharmacol; 2004 Sep; 56(9):1067-81. PubMed ID: 15324475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer chemoresistance; biochemical and molecular aspects: a brief overview.
    Kachalaki S; Ebrahimi M; Mohamed Khosroshahi L; Mohammadinejad S; Baradaran B
    Eur J Pharm Sci; 2016 Jun; 89():20-30. PubMed ID: 27094906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating ROS to overcome multidrug resistance in cancer.
    Cui Q; Wang JQ; Assaraf YG; Ren L; Gupta P; Wei L; Ashby CR; Yang DH; Chen ZS
    Drug Resist Updat; 2018 Nov; 41():1-25. PubMed ID: 30471641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines.
    Kars MD; Işeri OD; Gunduz U; Molnar J
    Chemotherapy; 2008; 54(3):194-200. PubMed ID: 18560226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.